Author:
Preisser Felix,Graefen Markus,Hansen Jens,Bastian Patrick J.,Schlomm Thorsten,Schwarz Rudolf,Huland Hartwig
Publisher
Springer Berlin Heidelberg
Reference97 articles.
1. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112:307–314
2. Ahmed HU, Cathcart P, Chalasani V, Williams A, McCartan N, Freeman A, Kirkham A, Allen C, Chin J, Emberton M (2011) Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer 118(12):3071–8
3. Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R (2017) Clinical impact of (68) Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int 120(2):197–203
4. Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A (2007) Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109(1):41–47
5. Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H (1999) Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 161:857–862; discussion 62–3